THE HIDDEN CULPRIT: PULMONARY TB COMPLICATING THE DIAGNOSIS AND TREATMENT OF ANTI-SRP IMMUNE MYOPATHY

Dr.Thuslim Banu K MD DM Resident, Prof Dr. Murugan MD DM (HOD of dept of neurology MMC)

Prof Dr. Justin MD DM, Asst prof Dr.D. Chezian, Dr. Venkateswaran K.J, Department of Neurology, Madurai Medical College



Background:

Anti-SRP IMNM is a rare, rapidly progressive autoimmune myopathy.

Presents with severe proximal weakness and marked CK elevation.

Muscle biopsy shows necrosis with scant inflammation.

Frequently refractory to conventional immunosuppression.

Aim:

To report a rare co-occurrence of anti-SRP IMNM with active pulmonary tuberculosis.

To highlight the **diagnostic overlap** and **treatment dilemma** in TB-endemic settings.

To discuss strategies for safe immunosuppression while controlling infection.

Methodology:

Young female with 8 months of rapidly progressive proximal > distal weakness (neck/trunk involvement; MRC 42).

Very high CK and anti-SRP positivity confirmed IMNM. Infection screening done prior to immunosuppression. Treated with high-dose IV steroids \rightarrow IVIG \rightarrow immunosuppressants, but minimal improvement.


Re-evaluation revealed active pulmonary TB.

ATT started, and **monthly IVIG** continued as a safer interim therapy.

Patient later developed dysphagia, dyspnea, palpitations, and further weakness progression.

PLEX (5 cycles) was initiated along with ongoing ATT, resulting in notable clinical recovery.

IMAGING & RESULTS



Muscle MRI: Edema and infiltration noted in hip extensors, posterior compartment of thigh and leg in T2w images.



CT chest: Left UL apical segment infiltration.

Sputum Ab : Positive

BAL: Negative

- Results:
- Minimal response to initial high-dose IV steroids.
- IVIG + immunosuppressants started, but active pulmonary TB was subsequently detected.
- ATT initiated, and monthly IVIG (×4 cycles) continued.
- Patient developed worsening proximal weakness with dysphagia, dyspnea, and palpitations.
- PLEX (×5 cycles) given along with ATT, resulting in:
 - Improved bulbar and respiratory symptoms
 - MRC sum score improved from $42 \rightarrow 48$

Discussion:

IMNM with anti-SRP is aggressive and often refractory to standard therapy. Coexistence with active pulmonary TB is extremely rare, complicating diagnosis and treatment.

Immunosuppression risks worsening TB, creating a therapeutic dilemma. IVIG and PLEX served as effective bridging therapies while TB was treated.

Highlights the need for individualized treatment, especially in TB-endemic regions.

Conclusion:

Anti-SRP IMNM may **coexist with pulmonary TB**, masking clinical response.

Routine TB screening is essential before initiating immunosuppression.

IVIG and PLEX can provide safe disease control when full immunosuppression is contraindicated.

Balanced immunotherapy + infection control is key to optimal outcomes.

References:

- 1. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. Immune-mediated necrotizing myopathies: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689-701.
- 2. Christopher-Stine L. Therapeutic challenges in necrotizing autoimmune myopathy. Rheum Dis Clin North Am. 2018;44(1):99-114.
 3. Sharma R, Gupta A. Active tuberculosis complicating immunosuppressive therapy in inflammatory myopathies: a management dilemma. Neurol India. 2021;69(4):1072-1074.